Endocannabinoid system modulation in cancer biology and therapy

Pharmacological Research

Volumn 60, Issue 2, 2009, Pages 107-116

  Pisanti, Simona ^a   Bifulco, Maurizio ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Cancer; Cancer treatment; Cannabinoid receptors; Endocannabinoid system

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENYLATE CYCLASE; ANANDAMIDE; ANTINEOPLASTIC AGENT; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CAY 10401; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; PROTEIN BAX; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; RIMONABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DISEASE MODEL; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; METASTASIS INHIBITION; NAUSEA; PAIN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CANCER; THYROID CANCER; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

ANIMALS; ENDOCANNABINOIDS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, CANNABINOID;

EID: 67449138588     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.03.011     Document Type: Review

References (107)

1. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
2. Bifulco M., and Di Marzo V. The endocannabinoid system as a target for the development of new drugs for cancer therapy. Nat Med 8 (2002) 547-550
3. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumor strategy. Br J Pharmacol 148 (2006) 123-135
4. Melck D., Rueda D., Galve-Roperh I., De Petrocellis L., Guzmán M., and Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463 (1999) 235-240
5. Portella G., Laezza C., Laccetti P., De Petrocellis L., Di Marzo V., and Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17 (2003) 1771-1773
6. Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (2003) 43-50
7. Mimeault M., Pommery N., Wattez N., Bailly C., and Hénichart J.P. Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56 (2003) 1-12
8. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95 (1998) 8375-8380
9. Melck D., De Petrocellis L., Orlando P., Bisogno T., Laezza C., Bifulco M., et al. Suppression of nerve growth factor Trk receptor and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 (2000) 118-126
10. Bifulco M., Malfitano A.M., Pisanti S., and Laezza C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15 (2008) 391-408
11. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65 (2005) 1635-1641
12. Held-Feindt J., Dörner L., Sahan G., Mehdorn H.M., and Mentlein R. Cannabinoid receptors in human astroglial tumors. J Neurochem 98 (2006) 886-893
13. Laezza C., Pisanti S., Crescenzi E., and Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 580 (2006) 6076-6082
14. Caffarel M.M., Sarrió D., Palacios J., Guzmán M., and Sánchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66 (2006) 6615-6621
15. Sarfaraz S., Afaq F., Adhami V.M., Malik A., and Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 281 (2006) 39480-39491
16. Galanti G., Fisher T., Kventsel I., Shoham J., Gallily R., Mechoulam R., et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 47 (2008) 1062-1070
17. Galve-Roperh I., Sánchez C., Cortés M.L., Gómez del Pulgar T., Izquierdo M., and Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6 (2000) 313-319
18. Gómez del Pulgar T., Velasco G., Sánchez C., Haro A., and Guzmán M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363 (2002) 183-188
19. Carracedo A., Gironella M., Lorente M., Garcia S., Guzmán M., Velasco G., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 66 (2006) 6748-6755
20. Gómez del Pulgar T., Velasco G., and Guzmán M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347 (2000) 369-373
21. Ellert-Miklaszewska A., Kaminska B., and Konarska L. Cannabinoids downregulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17 (2005) 25-37
22. Sarker K.P., Biswas K.K., Yamakuchi M., Lee K.Y., Hahiguchi T., Kracht M., et al. ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J Neurochem 85 (2003) 50-61
23. Hinz B., Ramer R., Eichele K., Weinzierl U., and Brune K. Up-regulation of cyclooxygenase-2 expression is involved in R(+)-methanandamide-induced apoptotic death of human neuroglioma cells. Mol Pharmacol 66 (2004) 1643-1651
24. Powles T., te Poele R., Shamash J., Chaplin T., Propper D., Joel S., et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105 (2005) 1214-1221
25. Sánchez C., Galve-Roperh I., Rueda D., and Guzmán M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54 (1998) 834-843
26. Gustafsson K., Christensson B., Sander B., and Flygare J. Cannabinoid receptormediated apoptosis induced by R(+)-methanandamide and Win55, 212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol 70 (2006) 1612-1620
27. Jia W., Hegde V.L., Singh N.P., Sisco D., Grant S., Nagarkatti M., et al. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4 (2006) 549-562
28. Herrera B., Carracedo A., Diez-Zaera M., Gómez del Pulgar T., Guzmán M., and Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res 312 (2006) 2121-2131
29. Athanasiou A., Clarke A.B., Turner A.E., Kumaran N.M., Vakilpour S., Smith P.A., et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364 (2007) 131-137
30. Greenhough A., Patsos H.A., Williams A.C., and Paraskeva C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121 (2007) 2172-2180
31. Cianchi F., Papucci L., Schiavone N., Lulli M., Magnelli L., Vinci M.C., et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 14 (2008) 7691-7700
32. Giuliano M., Pellerito O., Portanova P., Calvaruso G., Santulli A., De Blasio A., et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARgamma. Biochimie 91 (2009) 457-465
33. Shi Y., Zou M., Baitei E.Y., Alzahrani A.S., Parhar R.S., Al-Makhalafi Z., et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 15 (2008) 101-107
34. Ferrara N., and Kerbel R.S. Angiogenesis as a therapeutic target. Nature 438 (2005) 967-974
35. Blázquez C., Casanova M.L., Planas A., Del Pulgar T.G., Villanueva C., Fernández-Aceñero M.J., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17 (2003) 529-531
36. Blázquez C., Carracedo A., Barrado L., Real P.J., Fernández-Luna J.L., Velasco G., et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 20 (2006) 2633-2635
37. Blazquez C., Gonzalez-Feria L., Alvarez L., Haro A., Casanova M.L., and Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64 (2004) 5617-5623
38. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., and Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 211 (2007) 495-503
39. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312 (2006) 363-373
40. Joseph J., Niggemann B., Zaenker K.S., and Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53 (2004) 723-728
41. Ramer R., and Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100 (2008) 59-69
42. Preet A., Ganju R.K., and Groopman J.E. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (2008) 339-346
43. Nithipatikom K., Endsley M.P., Isbell M.A., Falck J.R., Iwamoto Y., Hillard C.J., et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64 (2004) 8826-8830
44. Endsley M.P., Thill R., Choudhry I., Williams C.L., Kajdacsy-Balla A., Campbell W.B., et al. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123 (2008) 1318-1326
45. Blázquez C., Salazar M., Carracedo A., Lorente M., Egia A., González-Feria L., et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 68 (2008) 1945-1952
46. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318 (2006) 1375-1387
47. Rajesh M., Mukhopadhyay P., Bátkai S., Haskó G., Liaudet L., Huffman J.W., et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293 (2007) H2210-H2218
48. Montecucco F., Burger F., Mach F., and Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294 (2008) H1145-H1155
49. Song Z.H., and Zhong M. CB1 cannabinoid receptor-mediated cell migration. J Pharmacol Exp Ther 294 (2000) 204-209
50. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174 (2005) 3281-3289
51. Caffarel M.M., Moreno-Bueno G., Cerutti C., Palacios J., Guzman M., Mechta-Grigoriou F., et al. JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene 27 (2008) 5033-5044
52. Sarnataro D., Pisanti S., Santoro A., Gazzerro P., Malfitano A.M., Laezza C., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid rafts mediated mechanism. Mol Pharmacol 70 (2006) 1298-1306
53. Takeda S., Yamaori S., Motoya E., Matsunaga T., Kimura T., Yamamoto I., et al. Delta(9)-tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 245 (2008) 141-146
54. Ruiz L., Miguel A., and Diaz-Laviada I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458 (1999) 400-404
55. Sánchez M.G., Sánchez A.M., Ruiz-Llorente L., and Díaz-Laviada I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555 (2003) 561-566
56. Sánchez C., de Ceballos M.L., Gomez del Pulgar T., Rueda D., Corbacho C., Velasco G., et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 61 (2001) 5784-5789
57. McAllister S.D., Chan C., Taft R.J., Luu T., Abood M.E., Moore D.H., et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74 (2005) 31-40
58. Bifulco M., Laezza C., Portella G., Vitale M., Orlando P., De Petrocellis L., et al. Control by the endogenous cannabinoid system of ras oncogene dependent tumor growth. FASEB J 15 (2001) 2745-2747
59. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., and Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18 (2004) 1606-1608
60. Maccarrone M., Lorenzon T., Bari M., Melino G., and Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors: evidence for a protective role of cannabinoid receptors. J Biol Chem 275 (2000) 31938-31945
61. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2002) 627-634
62. Flygare J., Gustafsson K., Kimby E., Christensson B., and Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579 (2005) 6885-6889
63. Herrera B., Carracedo A., Diez-Zaera M., Guzmán M., and Velasco G. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 579 (2005) 5084-5088
64. Gustafsson K., Wang X., Severa D., Eriksson M., Kimby E., Merup M., et al. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 123 (2008) 1025-1033
65. Patsos H.A., Hicks D.J., Dobson R.R., Greenhough A., Woodman N., Lane J.D., et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54 (2005) 1741-1750
66. Izzo A.A., Aviello G., Petrosino S., Orlando P., Marsicano G., Lutz B., et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 86 (2008) 89-98
67. Gustafsson S.B., Lindgren T., Jonsson M., and Jacobsson S.O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 63 (2009) 691-701
68. Wang D., Wang H., Ning W., Backlund M.G., Dey S.K., and DuBois R.N. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68 (2008) 6468-6476
69. DeMorrow S., Glaser S., Francis H., Venter J., Vaculin B., Vaculin S., et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 282 (2007) 13098-13113
70. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., and Carchman R.A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55 (1975) 597-602
71. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor _-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64 (2004) 1943-1950
72. Eichele K., Ramer R., and Hinz B. R(+)-methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway. Pharm Res 26 (2009) 346-355
73. Begg M., Pacher P., Bátkai S., Osei-Hyiaman D., Offertáler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 106 (2005) 133-145
74. Contassot E., Tenan M., Schnüriger V., Pelte M.F., and Dietrich P.Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93 (2004) 182-188
75. Sarnataro D., Grimaldi C., Pisanti S., Gazzerro P., Laezza C., Zurzolo C., et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579 (2005) 6343-6349
76. Bari M., Battista N., Fezza F., Finazzi-Agrò A., and Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280 (2005) 12212-12220
77. Yu M., Ives D., and Ramesha C.S. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272 (1997) 21181-21186
78. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277 (2002) 44877-44885
79. Van Dross RT. Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog, in press.
80. Massi P., Vaccani A., Ceruti S., Colombo A., Abbracchio M.P., and Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308 (2004) 838-845
81. Vaccani A., Massi P., Colombo A., Rubino T., and Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144 (2005) 1032-1036
82. McAllister S.D., Christian R.T., Horowitz M.P., Garcia A., and Desprez P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6 (2007) 2921-2927
83. Kogan N.M., Schlesinger M., Priel E., Rabinowitz R., Berenshtein E., Chevion M., et al. HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther 6 (2007) 173-183
84. Kogan N.M., Blázquez C., Alvarez L., Gallily R., Schlesinger M., Guzmán M., et al. A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol 70 (2006) 51-59
85. Liu W.M., Scott K.A., Shamash J., Joel S., and Powles T.B. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma 49 (2008) 1800-1809
86. Agner J., Falck J., Lukas J., and Bartek J. Differential impact of diverse anticancer chemotherapeutics on the Cdc25Adegradation checkpoint pathway. Exp Cell Res 302 (2005) 162-169
87. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 18 (2007) 129-140
88. Petersen G., Moesgaard B., Schmid P.C., Schmid H.H., Broholm H., Kosteljanetz M., et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem 93 (2005) 299-309
89. Pagotto U., Marsicano G., Fezza F., Theodoropoulou M., Grubler Y., Stalla J., et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86 (2001) 2687-2696
90. Schmid P.C., Wold L.E., Krebsbach R.J., Berdyshev E.V., and Schmid H.H. Anandamide and other N-acylethanolamines in human tumors. Lipids 37 (2002) 907-912
91. Nithipatikom K., Endsley M.P., Isbell M.A., Falck J.R., IwamotoY, Hillard C.J., et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64 (2004) 8826-8830
92. Ligresti A., Bisogno T., Matias I., De Petrocellis L., Cascio M.G., Cosenza V., et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125 (2003) 677-687
93. Michalski C.W., Oti F.E., Erkan M., Sauliunaite D., Bergmann F., Pacher P., et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122 (2008) 742-750
94. Calatozzolo C., Salmaggi A., Pollo B., Sciacca F.L., Lorenzetti M., Franzini A., et al. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol Sci 28 (2007) 304-310
95. Islam T.C., Asplund A.C., Lindvall J.M., Nygren L., Liden J., Kimby E., et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17 (2003) 1880-1890
96. Czifra G., Varga A., Nyeste K., Marincsák R., Tóth B.I., Kovács I., et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol 135 (2009) 507-514
97. Chung S.C., Hammarsten P., Josefsson A., Stattin P., Granfors T., Egevad L., et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 45 (2009) 174-182
98. Xu X., Liu Y., Huang S., Liu G., Xie C., Zhou J., et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171 (2006) 31-38
99. Pisanti S., Malfitano A.M., Grimaldi C., Santoro A., Gazzerro P., Laezza C., et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 23 (2009) 117-131
100. Walsh D., Nelson K.A., and Mahmoud F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11 (2003) 137-143
101. Guzmán M., Duarte M.J., Blázquez C., Ravina J., Rosa M.C., Galve-Roperh I., et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 95 (2006) 197-203
102. Derocq J.M., Bouaboula M., Marchand J., Rinaldi-Carmona M., Ségui M., and Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425 (1998) 419-425
103. Börner C., Höllt V., Sebald W., and Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 81 (2007) 336-343
104. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 13 (2007) 35-37
105. Notarnicola M., Messa C., Orlando A., Bifulco M., Laezza C., Gazzerro P., et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 43 (2008) 66-72
106. Begum S., Emami N., Cheung A., Wilkins O., Der S., and Hamel P.A. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR. Oncogene 24 (2005) 1860-1872
107. Ryberg E., Vu H.K., Larsson N., Groblewski T., Hjorth S., Elebring T., et al. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579 (2005) 259-264